AC Immune SA

NASDAQ:ACIUUnited States

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact Information

Headquarters

EPFL Innovation Park, Building BLAUSANNE, Switzerland 1015

Phone

---

Fax

---

Executives

Independent Chairman of the Board

Douglas Williams

Chief Executive Officer, Co-Founder, Director

Andrea Pfeifer

Chief Technical Operations Officer

Piergiorgio Donati

Chief Human Resource Officer

Howard Donovan

Chief Administrative Officer

Jean-Fabien Monin